Veristat Executive and Leadership Team

Kim McLean Boericke, the Chief Executive Officer at Veristat, directs the company's overarching strategy and operational execution. Boericke guides the organization's mission to support pharmaceutical, biotechnology, and medical device companies through complex clinical trials and regulatory submissions. This leadership involves fostering a science-focused culture that prioritizes data integrity and patient outcomes. Boericke ensures Veristat's services align with industry advancements and client needs, driving the company's growth and market position. The Chief Executive Officer's focus remains on enhancing Veristat's capabilities to deliver critical insights and accelerate drug development timelines. Kim McLean Boericke's strategic vision shapes the company's direction, ensuring continued innovation and client success in a dynamic global landscape.

David Koster, the Co-Founder & Chief Executive Officer at Veristat, spearheads the company's strategic vision and foundational principles. Koster's leadership is integral to Veristat's identity as a science-focused clinical research organization, emphasizing a commitment to supporting pharmaceutical, biotechnology, and medical device clients. This role involves shaping the company's long-term objectives and ensuring its continued evolution in the research landscape. David Koster's influence extends to fostering partnerships and driving initiatives that enhance Veristat's service offerings. The Co-Founder & Chief Executive Officer's dedication to scientific integrity and client success underpins the organization's operational framework. Through strategic guidance, Koster ensures Veristat remains at the forefront of clinical trial support and regulatory submission expertise.

Joshua Korth, the Chief Financial Officer at Veristat, manages the company's financial health and strategic fiscal planning. Korth oversees all financial operations, including budgeting, forecasting, and resource allocation, ensuring robust financial infrastructure to support Veristat's growth as a full-service clinical research organization. This leadership position involves optimizing financial performance and driving profitability while maintaining compliance with industry standards. Joshua Korth's responsibilities extend to managing investments and financial risk, crucial for supporting pharmaceutical, biotechnology, and medical device clients through their clinical trials and regulatory submissions. The Chief Financial Officer's strategic financial insights enable informed decision-making across all departments. By ensuring financial stability, Joshua Korth directly contributes to Veristat's capacity for innovation and sustained client support.

John Balser, the Founder & President & Statistical Chief & Officer at Veristat, establishes the company's core scientific and operational direction. Balser's multifaceted role encompasses leadership in statistical analysis, a critical component for supporting clinical trials and regulatory submissions for pharmaceutical, biotechnology, and medical device companies. This position involves driving innovation in data interpretation and ensuring the highest standards of scientific rigor across all projects. John Balser's influence as President guides the overall organizational strategy and operational efficiency. The Founder & President & Statistical Chief & Officer's deep expertise in statistical methodologies underpins Veristat's reputation for scientific excellence. Through this leadership, John Balser ensures the company consistently delivers high-quality, data-driven insights that advance client research and development efforts.